Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 6, Pages 553-559
Publisher
Informa UK Limited
Online
2018-06-02
DOI
10.1080/13543784.2018.1484107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
- (2017) Howard I. Scher et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2017) Nicolas Mottet et al. EUROPEAN UROLOGY
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
- (2016) Athanasios Dellis et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel and next-generation androgen receptor–directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
- (2016) Richard M. Bambury et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
- (2015) DJ Crona et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Observational studies and the natural history of screen-detected prostate cancer
- (2015) Peter C. Albertsen CURRENT OPINION IN UROLOGY
- Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
- (2015) Theodoros Karantanos et al. EUROPEAN UROLOGY
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment
- (2015) Michael S. Cookson et al. JOURNAL OF UROLOGY
- Androgen receptor aberrations in the era of abiraterone and enzalutamide
- (2015) Florian Jentzmik et al. WORLD JOURNAL OF UROLOGY
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
- (2013) Paul J Toren et al. ASIAN JOURNAL OF ANDROLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started